- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-HER2/ErbB2
HER2/ErbB2 Polyclonal Antibody for WB, IP, IF, IHC, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, souris et plus (1)
Applications
WB, IHC, IF-P, IP, ELISA
Conjugaison
Non conjugué
N° de cat : 18299-1-AP
Synonymes
Galerie de données de validation
Applications testées
Résultats positifs en WB | cellules 4T1, cellules HeLa, cellules MCF-7, cellules SGC-7901 |
Résultats positifs en IP | cellules SGC-7901 |
Résultats positifs en IHC | tissu de cancer du sein humain, il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
Résultats positifs en IF-P | tissu de cancer du sein humain, |
Dilution recommandée
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:2000-1:12000 |
Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
Immunohistochimie (IHC) | IHC : 1:300-1:1200 |
Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Applications publiées
KD/KO | See 2 publications below |
WB | See 46 publications below |
IHC | See 12 publications below |
IF | See 6 publications below |
FC | See 1 publications below |
Informations sur le produit
18299-1-AP cible HER2/ErbB2 dans les applications de WB, IHC, IF-P, IP, ELISA et montre une réactivité avec des échantillons Humain, souris
Réactivité | Humain, souris |
Réactivité citée | rat, Humain, souris |
Hôte / Isotype | Lapin / IgG |
Clonalité | Polyclonal |
Type | Anticorps |
Immunogène | Peptide |
Nom complet | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
Masse moléculaire calculée | 138 kDa |
Poids moléculaire observé | 185 kDa |
Numéro d’acquisition GenBank | BC167147 |
Symbole du gène | HER2/ErbB2 |
Identification du gène (NCBI) | 2064 |
Conjugaison | Non conjugué |
Forme | Liquide |
Méthode de purification | Purification par affinité contre l'antigène |
Tampon de stockage | PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3 |
Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.
Protocole
Product Specific Protocols | |
---|---|
WB protocol for HER2/ErbB2 antibody 18299-1-AP | Download protocol |
IHC protocol for HER2/ErbB2 antibody 18299-1-AP | Download protocol |
IF protocol for HER2/ErbB2 antibody 18299-1-AP | Download protocol |
IP protocol for HER2/ErbB2 antibody 18299-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Cell Metab Targeting Erbin-mitochondria axis in platelets/megakaryocytes promotes B cell-mediated antitumor immunity | ||
Cell Res Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. | ||
Small Efficient Delivery of GSDMD-N mRNA by Engineered Extracellular Vesicles Induces Pyroptosis for Enhanced Immunotherapy | ||
Nat Commun Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. | ||
J Immunother Cancer Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells. | ||
Cancer Res Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. |
Avis
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
FH Vanina (Verified Customer) (07-28-2021) | MDA-MB-453 cell line was transfected with different concentrations of HER2/Erbb2 siRNA for 48h. Western blot using HER2/Erbb2 rabbit Proteintech antibody (18299-1-AP) at 1:2,000 dillution confirms the HER2/Erbb2 knockdown.
|